PubMed=18682896; DOI=10.1007/s11010-008-9892-4
Cho H., Kang E.S., Hong S.W., Oh Y.J., Choi S.M., Kim S.W., Kim S.H., Kim Y.T., Lee K.S., Choi Y.K., Kim J.-H.
Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line.
Mol. Cell. Biochem. 319:189-201(2008)

PubMed=19188485; DOI=10.1369/jhc.2009.953257; PMCID=PMC2675069
Cho H., Kim J.-H.
Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.
J. Histochem. Cytochem. 57:513-521(2009)

PubMed=20596667; DOI=10.3892/ijo_00000688
Chay D.B., Cho H., Lim B.J., Kang E.S., Oh Y.J., Choi S.M., Kim B.W., Kim Y.T., Kim J.-H.
ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139.
Int. J. Oncol. 37:399-412(2010)

PubMed=24164300; DOI=10.3109/07357907.2013.849722
Cho H., Lee Y.S., Kim J., Chung J.-Y., Kim J.-H.
Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer.
Cancer Invest. 31:607-615(2013)

PubMed=31615043; DOI=10.3390/cancers11101553; PMCID=PMC6826427
Choi J.-A., Kwon H., Cho H., Chung J.-Y., Hewitt S.M., Kim J.-H.
ALDH1A2 is a candidate tumor suppressor gene in ovarian cancer.
Cancers (Basel) 11:1553.1-1553.18(2019)